Skip to content

Randomised trial, 2005

Does paroxetine controlled-release help PMDD?

Yes. Both 12.5 mg and 25 mg doses of paroxetine were more effective than placebo for PMDD mood symptoms and were well tolerated.

Strong study design Women aged 18-45 with confirmed PMDD from 47 centers in US and Canada

What they did

Women aged 18-45 with diagnosed PMDD were recruited from 47 treatment centers across the United States and Canada. After screening and a placebo period, they were randomly assigned to receive paroxetine 12.5 mg, 25 mg, or placebo daily for 3 menstrual cycles. Symptoms were measured using a mood scale tracking irritability, tension, depressed mood, and emotional changes.

What they found

Both doses of paroxetine significantly improved mood symptoms more than placebo, with the 25 mg dose showing greater improvement than the 12.5 mg dose. Paroxetine was well tolerated with no more side effects than placebo.

What it means for you

Paroxetine controlled-release appears effective for PMDD, with 25 mg being stronger than 12.5 mg. Both doses are well tolerated. This comes from a multi-center trial, though the exact number of women studied is not stated in the abstract.

47

treatment centers

12.5 or 25 mg

daily doses tested

3

menstrual cycles of treatment

About the study

Original title
Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial
Authors
Pearlstein TB, Bellew KM, Endicott J et al.
Journal
Primary care companion to the Journal of clinical psychiatry
Year
2005
Study design
Randomised trial
Participants
3
What was tested
Paroxetine 12.5 mg or 25 mg daily versus placebo over 3 cycles
Open access
Yes

Topics